首页> 外文期刊>Current medical research and opinion >Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.
【24h】

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.

机译:在亚洲国家和地区的高胆固醇血症患者中,他汀类药物治疗后达到胆固醇目标的现状:亚洲脂质治疗的费用回报率研究(REALITY-Asia)。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Data on achieving National Cholesterol Education Program Adult Treatment Panel III (ATP III) goals in Asia are limited. OBJECTIVE: To examine treatment patterns, goal attainment, and factors influencing treatment among patients in 6 Asian countries who were taking statins. METHODS: A retrospective cohort study was conducted in China, Korea, Malaysia, Singapore, Taiwan, and Thailand, where 437 physicians (41% cardiologists) recruited adults with hypercholesterolemia newly initiated on statin monotherapy. RESULTS: Of 2622 patients meeting inclusion and exclusion criteria, approximately 66% had coronary heart disease (CHD)/diabetes mellitus, 24% had no CHD but > or =2 risk factors, and 10% had no CHD and <2 risk factors. Most patients ( approximately 90%) received statins at medium or lower equipotency doses. Across all cardiovascular risk categories, 48% of patients attained ATP III targets for low-density lipoprotein cholesterol (LDL-C), including 38% of those with CHD/diabetes (goal: <100 mg/dL), 62% of those without CHD but with > or =2 risk factors (goal: <130 mg/dL), and 81% of those without CHD and <2 risk factors (goal: <160 mg/dL). Most patients who achieved goals did so within the first 3 months. Increasing age (odds ratio (OR)=1.015 per 1-year increment; 95% confidence interval (CI)=1.005-1.206; p=0.0038) and initial statin potency (OR=2.253; 95% CI=1.364-3.722; p=0.0015) were directly associated with goal attainment, whereas increased cardiovascular risk (OR=0.085; 95% CI=0.053-0.134; p<0.0001 for CHD/diabetes mellitus at baseline compared with <2 risk factors,) and baseline LDL-C (OR=0.990; 95% CI=0.987-0.993); p<0.0001 per 1-mg/dL increment) were inversely associated with LDL-C goal achievement. Limitations of this study include potential differences in treatment settings and cardiovascular risk factors between different countries and centers. In addition, the effects on cholesterol goal achievement of concomitant changes in lifestyle were not assessed. CONCLUSION: LDL-C goal attainment is low in Asians, particularly those with CHD/diabetes. More effective patient monitoring, treatments, including combining regimens and dose titration, and adherence to these treatments along with therapeutic lifestyle counseling may facilitate goal attainment.
机译:背景:在亚洲实现国家胆固醇教育计划成人治疗小组III(ATP III)目标的数据有限。目的:研究亚洲6个接受他汀类药物治疗的患者的治疗方式,目标达成情况以及影响治疗的因素。方法:在中国,韩国,马来西亚,新加坡,台湾和泰国进行了一项回顾性队列研究,其中437名医生(占心脏病专家的41%)招募了他汀类药物单一疗法新近引发的高胆固醇血症的成年人。结果:在满足纳入和排除标准的2622名患者中,大约66%患有冠心病(CHD)/糖尿病,24%没有CHD但≥2的危险因素,10%没有CHD和<2危险的因素。大多数患者(约90%)以中等或更低的等剂量剂量接受他汀类药物。在所有心血管疾病风险类别中,有48%的患者达到了低密度脂蛋白胆固醇(LDL-C)的ATP III目标,包括38%的患有CHD /糖尿病的患者(目标:<100 mg / dL),62%的未患有心血管疾病的患者冠心病但有>或= 2危险因素(目标:<130 mg / dL),无冠心病且<2危险因素(目标:<160 mg / dL)的有81%。大多数达到目标的患者在头3个月内就达到了目标。年龄增长(每1年增加的比值(OR)= 1.015; 95%置信区间(CI)= 1.005-1.206; p = 0.0038)和初始他汀类药物效价(OR = 2.253; 95%CI = 1.364-3.722; p = 0.0015)与目标达成直接相关,而心血管风险增加(OR = 0.085; 95%CI = 0.053-0.134;基线时CHD /糖尿病的p <0.0001,而低于<2个危险因素),以及基线LDL-C (OR = 0.990; 95%CI = 0.987-0.993); p <0.0001 / 1-mg / dL增量)与LDL-C目标达成成反比。该研究的局限性包括不同国家和中心之间在治疗环境和心血管危险因素方面的潜在差异。此外,未评估生活方式随之改变对胆固醇目标达成的影响。结论:亚洲人,特别是患有冠心病/糖尿病的亚洲人的LDL-C目标达成率较低。更有效的患者监测,治疗(包括方案和剂量滴定相结合)以及对这些治疗的依从性以及治疗性生活方式咨询可能会促进目标的实现。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号